CMP as on 19-May-22 15:30₹ 101.00
Turnover (lac)₹ 16
Prev. Close₹ 104.80
Day's Vol (shares)₹ 15,465
Day's Range (₹)
CMP as on19-May-22 15:28₹ 101.70
Turnover (lac)₹ 6
Prev. Close₹ 104.50
Day's Vol (shares)₹ 1,077
The ratings for long-term fund-based facilities and long-term term loan facilities have been upgraded to BBB- from BB+ indicating a Sta
The companys Short term Non-fund based facilities were assigned ACUITE A3 from earlier ICRA A4+.
The rating has been reaffirmed on long-term fund-based facilities at ICRA BB+ and short-term rating at ICRA A4+.
Bal Pharma is one of the largest producers and exporters of an API Gliclazide, which is used to treat type 2 diabetes.
The rating on long-term fund-based facilities of the company has been upgraded to ICRA BB+; Stable.
Whereas in another transaction of bulk deals, Munish Financial bought 14 lakh equity shares in Gayatri Projects at Rs47.88 per share on
The company has delivered an all-round performance with Revenue registering a growth of 36% yoy to Rs71cr in Q1FY22.
Favipiravir an emerging antiviral drug, is used for patients with mild to moderate Covid-19 infection.
The acquisition is done through preferential issue upon conversion of warrants.
Short term non-fund based instruments has been reaffirmed to [ICRA]A4.
Per Order for ETF & Mutual Funds Brokerage
Per Order for Delivery, Intraday, F&O, Currency & Commodity